این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Journal of Research in Medical Sciences، جلد ۱۷، شماره ۰۳، صفحات ۰-۰
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Associations of oral L-carnitine with hemoglobin, lipid profile, and albumin in hemodialysis patients
چکیده انگلیسی مقاله Normal 0 false false false EN-US X-NONE AR-SA MicrosoftInternetExplorer4 BACKGROUND : Previous reports have suggested acute phase proteins, such as albumin, to alter in hemodialysis (HD) patients. Intravenous L-carnitine supplementation is expected to improve the level of plasma albumin in HD patients. This study was performed to evaluate the effects of oral L-carnitine supplementation on hemoglobin, lipid profile, and albumin in HD patients. METHODS : In a double-blind, placebo-controlled study during October 2008 to April 2010, 54 HD patients were randomly assigned into 3 groups to receive 750 mg/day oral L-carnitine (17 patients), placebo (19 patients), or nothing (control group, 18 patients) for 6 months. Eligible patients for the study were above 21 years old, had no carnitine during the previous month, and had signed the informed consent to enter the study. The primary outcome was plasma albumin level. The secondary outcomes were hemoglobin level, erythropoietin (EPO) doses, lipid profile [high-density lipoprotein (HDL), low-density lipoprotein (LDL), cholesterol, and triglyceride), and side effects of L-carnitine. Patients were followed for side effects. The results were analyzed by SPSS17. RESULTS : Before administration of L-carnitine, the mean levels of hemoglobin were 10.81 ± 1.20 mg/dl in the L-carnitine group, and 9.85 ± 1.13 mg/dl in the placebo group. At the end of the study, hemoglobin level was 11.6 ± 1.05 mg/dl in the L-carnitine group and 10.33 ± 1.08 mg/dl in the placebo group. Therefore, hemoglobin levels rose significantly in the L-carnitine group (p = 0.04) but not in the placebo group (p > 0.05). HDL decreased in the placebo group but had no changes in the L-carnitine group. Cholesterol, triglyceride, and LDL did not change during 6 months (p > 0.05). Side effects did not increase in the L-carnitine group. CONCLUSIONS : Administration of 750 mg/day oral L-carnitine for 6 months had beneficial effects on hemoglobin and HDL, but not on albumin and the required EPO. Studies with higher doses of oral L-carnitine or in peritoneal dialysis patients are suggested. KEYWORDS : L-Carnitine; Kidney Failure; Chronic; Acute-Phase Proteins
کلیدواژه‌های انگلیسی مقاله Carnitine,Kidney Failure, Chronic,Acute-Phase Proteins
نویسندگان مقاله مژگان مرتضوی | mojgan mortazavi
assistant professor of nephrology, isfahan kidney diseases research center, isfahan university of medical sciences, isfahan, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی اصفهان (Isfahan university of medical sciences)

شیوا صیرفیان | shiva seirafian
assistant professor of nephrology, isfahan kidney diseases research center, isfahan university of medical sciences, isfahan, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی اصفهان (Isfahan university of medical sciences)

افروز اسحاقیان | afrooz eshaghian
resident of otolaryngology, isfahan kidney diseases research center and student research committee, isfahan university of medical sciences, isfahan, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی اصفهان (Isfahan university of medical sciences)

مریم قسامی | maryam ghassami
resident of internal medicine, isfahan kidney diseases research center, shahid beheshti university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی شهید بهشتی (Shahid beheshti university of medical sciences)

شهرام طاهری | shahram taheri
assistant professor of nephrology, isfahan kidney diseases research center, isfahan university of medical sciences, isfahan, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی اصفهان (Isfahan university of medical sciences)

عبدالامیر عطاپور | abdolamir atapour
assistant professor of nephrology, isfahan kidney diseases research center, isfahan university of medical sciences, isfahan, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی اصفهان (Isfahan university of medical sciences)

اکبر حسن زاده | akbar hassanzadeh
school of public health, isfahan university of medical sciences, isfahan , iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی اصفهان (Isfahan university of medical sciences)

احمد بیات | ahmad bayat
assistant professor of nephrology, najaf abad university of medical sciences, isfahan, iran


فیروزه معین زاده | firoozeh moinzadeh
resident of internal medicine, isfahan kidney diseases research center and student research committee, isfahan university of medical sciences, isfahan, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی اصفهان (Isfahan university of medical sciences)

نشانی اینترنتی http://jrms.mui.ac.ir/index.php/jrms/article/view/8160
فایل مقاله اشکال در دسترسی به فایل - ./files/site1/rds_journals/218/article-218-331006.pdf
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده Original Articles
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات